Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway

, Frontiers Editorial Office

doi:10.3389/fphar.2024.1530358

RETRACTION article

Front. Pharmacol. , 05 December 2024

Sec. Renal Pharmacology

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1530358

This article is part of the Research Topic Innovative Biologics and Drugs to Target Renal Inflammation View all 10 articles

Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway

This article is a retraction of:

RETRACTED: CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway
1. Read original article

Frontiers Editorial Office*

A Retraction of the Original Research Article
CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway

by Sun M-Y, Wang S-J, Li X-Q, Shen Y-L, Lu J-R, Tian X-H, Rahman K, Zhang L-J, Nian H and Zhang H (2019). Front. Pharmacol. 10:224. doi: 10.3389/fphar.2019.00224

The journal retracts the 25 March 2019 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in Figure 6C. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.

Citation: Frontiers Editorial Office (2024) Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway. Front. Pharmacol. 15:1530358. doi: 10.3389/fphar.2024.1530358

Received: 18 November 2024; Accepted: 25 November 2024;
Published: 05 December 2024.

Approved by:

Giuseppe Remuzzi, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Italy

Copyright © 2024 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Retraction: CXCL6 promotes renal interstitial fibrosis in diabetic nephropathy by activating JAK/STAT3 signaling pathway

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good